1p loss of heterozygosity (LOH)
Associated Cancer Type(s): Wilms tumor.

Significance/Prognosis: An unfavorable biomarker for Wilms tumor. Patients with combined LOH at 1p and 16q may not be suitable for therapy de-intensification.

Detection Method(s): Cytogenetic and molecular testing for LOH of 1p is recommended for all newly diagnosed Wilms tumors.

Therapeutic Implications: The prognostic significance implies treatment considerations, though specific therapies are not explicitly stated.

1q gain/amplification
Associated Cancer Type(s): Multiple Myeloma (MM), Wilms tumor.

Significance/Prognosis:

For MM: Part of the FISH panel for prognostic estimation of plasma cells. Defined as 3 copies of 1q21.

For Wilms tumor: An unfavorable biomarker. Can be used to identify patients who are not appropriate for de-intensification of therapy.

Detection Method(s): FISH. Cytogenetic and molecular testing for 1q gain is recommended for all newly diagnosed Wilms tumors.

Therapeutic Implications: For Wilms tumor, 1q gain can be used to identify patients who are not appropriate for de-intensification of therapy.

11p15 LOH/LOI (Loss of Heterozygosity/Loss of Imprinting)
Associated Cancer Type(s): Wilms tumor.

Significance/Prognosis: Fewer data support its use as an unfavorable biomarker. A retrospective analysis suggested patients with favorable histology Wilms tumor (FHWT) and 11p15 LOH or LOI may not be suitable for reduction of therapy (observation without adjuvant chemotherapy).

Syndrome Association: Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5.

Therapeutic Implications: May indicate that reduction of therapy is not suitable for patients with FHWT.

11q aberrations
Associated Cancer Type(s): Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma (HGBL), Burkitt Lymphoma (BL).

Significance/Prognosis: Large B-Cell Lymphoma (LBCL) with 11q aberration is a provisional entity, previously known as Burkitt-like lymphoma with 11q aberration. This disease is characterized by deregulation of the 11q gene but lacks MYC rearrangements.

Detection Method(s): Chromosomal microarray. Genetic testing includes 11q aberrations. FISH for MYC rearrangements is negative.

Therapeutic Implications: Often treated like Burkitt Lymphoma, though optimal management is undefined.

16q loss of heterozygosity (LOH)
Associated Cancer Type(s): Wilms tumor.

Significance/Prognosis: An unfavorable biomarker for Wilms tumor. Patients with combined LOH at 1p and 16q may not be suitable for therapy de-intensification.

Detection Method(s): Cytogenetic and molecular testing for LOH of 16q is recommended for all newly diagnosed Wilms tumors.

Therapeutic Implications: The prognostic significance implies treatment considerations.

ABL1 (gene rearrangement / fusion)
Associated Cancer Type(s): Myeloid/Lymphoid Neoplasms with Eosinophilia (MLNE), Chronic Myeloid Leukemia (CML) (as BCR::ABL1 fusion).

Significance/Prognosis:

One of the tyrosine kinase (TK) gene fusions associated with MLNE. ETV6::ABL1 gene fusion can be missed with routine cytogenetics.

For CML, BCR::ABL1 is the defining characteristic and is quantitatively monitored to assess disease burden.

Detection Method(s):

For ABL1 rearrangements: FISH, RT-PCR, RNA sequencing, NGS.

For CML (BCR::ABL1): Quantitative RT-PCR (qPCR) is essential. FISH and mutational analysis are also used.

Therapeutic Implications:

For MLNE with ABL1 rearrangement: Dasatinib, Nilotinib, Asciminib, Bosutinib, Imatinib, Ponatinib.

For CML (BCR::ABL1): Imatinib is standard therapy. Asciminib is an option for T315I mutation or resistance to prior TKIs.

AKT1
Associated Cancer Type(s): Breast Cancer.

Significance/Prognosis: Mutations/alterations may be found in breast cancer.

Therapeutic Implications: A target for PI3K inhibitors.

ALK (Anaplastic Lymphoma Kinase)
Associated Cancer Type(s): ALK-positive Large B-Cell Lymphoma (LBCL), Histiocytic Neoplasms (LCH, ECD, RDD), Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders (PCTLD), Anaplastic Large-Cell Lymphoma (ALCL), Non-Small Cell Lung Cancer (NSCLC), Sarcoma, Neuroblastoma, Thyroid Carcinoma.

Significance/Prognosis:

ALK alterations are important for neuroblastoma management and prognosis.

STRN-ALK fusion is a potential therapeutic target in aggressive thyroid cancers.

Detection Method(s): FISH, IHC, NGS.

Therapeutic Implications:

Histiocytic Neoplasms: Crizotinib, Alectinib, Brigatinib, Ceritinib, Lorlatinib.

NSCLC: Alectinib, brigatinib, ceritinib, crizotinib, or lorlatinib. ALK rearrangements are associated with less benefit from PD-1/PD-L1 inhibitors.

Sarcoma: Crizotinib for ALK fusions.

Neuroblastoma: ALK inhibitors are being investigated in clinical trials.

Anaplastic Thyroid Carcinoma: Molecular testing should include ALK.

APC
Associated Cancer Type(s): Familial Adenomatous Polyposis (FAP).

Significance/Prognosis: APC mutation analysis can contribute to therapeutic decisions in FAP. Desmoid risk in FAP patients is linked to early colectomy.

Detection Method(s): APC mutation analysis.

Therapeutic Implications: Guides therapeutic decisions in FAP.

AR (Androgen Receptor)
Associated Cancer Type(s): Salivary gland tumors, Prostate Carcinoma.

Significance/Prognosis: Gene expression analysis can identify mechanisms of therapy resistance in prostate carcinoma.

Detection Method(s): NGS profiling and other appropriate biomarker testing should check the status of at least the AR in salivary gland tumors.

Therapeutic Implications: For AR-positive salivary gland tumors, Abiraterone + prednisone + LHRH agonist is a recommended therapy regimen.

ARAF
Associated Cancer Type(s): Histiocytic Neoplasms (LCH, ECD, RDD).

Significance/Prognosis: A common mutation in the MAPK pathway in LCH and ECD.

Detection Method(s): Targeted-capture, Next-Generation Sequencing (NGS).

Therapeutic Implications: As part of the MAPK pathway, MEK inhibitors are relevant.

ASXL1
Associated Cancer Type(s): Acute Myeloid Leukemia (AML), Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Myelodysplastic Syndromes (MDS), Myeloid/Lymphoid Neoplasms with Eosinophilia (MLNE), Myeloproliferative Neoplasms (MPN), specifically Myelofibrosis (MF), Chronic Myeloid Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML).

Significance/Prognosis:

Has prognostic significance in AML and is part of the definition for AML-myelodysplasia-related (AML-MR).

One of the most frequently mutated genes in clonal hematopoiesis of indeterminate potential (CHIP).

Adverse mutation in primary myelofibrosis.

Detection Method(s): Multiplex gene panels and targeted NGS analysis.

Therapeutic Implications: No specific therapies are mentioned for ASXL1 mutations.

ATM
Associated Cancer Type(s): Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Ovarian Cancer, Prostate Cancer.

Significance/Prognosis:

In CLL/SLL, del(11q) affects ATM and is informative for prognosis.

Germline mutations are associated with a risk for lethal prostate cancer and gastric cancer.

Detection Method(s): Genetic testing for homologous recombination genes.

Therapeutic Implications: Mutations in ATM inform the use of PARP inhibitors in ovarian and prostate cancer. Somatic testing is recommended in metastatic prostate cancer.

Genetic Counseling: Recommended due to association with inherited genetic syndromes.

ATR
Associated Cancer Type(s): Ovarian Cancer, Prostate Cancer.

Significance/Prognosis: A DNA repair gene.

Therapeutic Implications: Mutations inform the use of PARP inhibitor therapy in ovarian cancer.

BAP1
Associated Cancer Type(s): Mesothelioma (Pleural & Peritoneal), Uveal Melanoma, Kidney Cancer.

Significance/Prognosis:

Mesothelioma: Loss of BAP1 by IHC is associated with prolonged survival and helps differentiate from benign proliferations.

Uveal Melanoma: A high-risk gene for distant metastasis. Associated with BAP1 Tumor Predisposition Syndrome.

Detection Method(s): IHC for BAP1 expression.

Therapeutic Implications: Prognostic significance guides management and surveillance strategies.

BARD1
Associated Cancer Type(s): Prostate Cancer, Neuroblastoma.

Significance/Prognosis: Germline variants in neuroblastoma predict worse survival.

Therapeutic Implications: For Prostate Cancer, mutations inform the use of PARP inhibitors (e.g., olaparib).

BCOR
Associated Cancer Type(s): Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloid/Lymphoid Neoplasms with Eosinophilia (MLNE), Pediatric undifferentiated sarcomas.

Significance/Prognosis:

Part of the definition for AML-myelodysplasia-related (AML-MR).

A main effect gene in the IPSS-M for MDS.

Therapeutic Implications: BCOR::CCNB3 fusion-positive tumors can be treated like Ewing sarcoma.

BCORL1
Associated Cancer Type(s): Myelodysplastic Syndromes (MDS).

Significance/Prognosis: A residual gene in the Molecular International Prognosis Scoring System (IPSS-M) for MDS.

BCL2
Associated Cancer Type(s): Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma (HGBL), HIV-related B-Cell Lymphomas, Post-Transplant Lymphoproliferative Disorders (PTLD), Primary Cutaneous B-Cell Lymphomas (PCBCL).

Significance/Prognosis: BCL2 rearrangements are key markers in lymphomas. HGBL with MYC and BCL2 rearrangements ("double-hit") is a recognized high-risk entity.

Detection Method(s): FISH, IHC.

Therapeutic Implications: Presence influences prognosis and treatment strategies, especially in "double-hit" lymphomas.

BCL6
Associated Cancer Type(s): Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), High-Grade B-Cell Lymphoma (HGBL), HIV-related B-Cell Lymphomas, Post-Transplant Lymphoproliferative Disorders (PTLD), Primary Cutaneous B-Cell Lymphomas (PCBCL).

Significance/Prognosis: BCL6 rearrangements are key markers in lymphomas. HGBL with MYC and BCL6 rearrangements is a recognized high-risk entity.

Detection Method(s): Karyotype or FISH, IHC.

Therapeutic Implications: No specific therapies are mentioned directly for BCL6 rearrangements.

BIRC3
Associated Cancer Type(s): Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

Significance/Prognosis: Mutations support the diagnosis of MCL and have clinical significance in CLL/SLL.

BRAF
Associated Cancer Type(s): Histiocytic Neoplasms (LCH, ECD, RDD), Marginal Zone Lymphomas (MZL), Hairy Cell Leukemia (HCL), Cutaneous Melanoma, Esophageal/Gastric Cancers, Pancreatic Cancer, GIST, Thyroid Carcinoma, and many others.

Significance/Prognosis: BRAF V600E is a common and important mutation across many cancers, often with prognostic significance (e.g., worse prognosis in thyroid cancer).

Detection Method(s): BRAF V600E IHC (VE1), allele-specific PCR, NGS, FISH for fusions.

Therapeutic Implications:

Histiocytic Neoplasms (V600E): Vemurafenib, Cobimetinib, Dabrafenib, Trametinib.

Melanoma (V600E): Dabrafenib/trametinib.

Esophageal/EGJ Cancers (V600E): Dabrafenib and trametinib.

Pancreatic Cancer (V600E): Dabrafenib + trametinib.

GIST (V600E): Dabrafenib and trametinib.

Thyroid Carcinoma (V600E): Dabrafenib/trametinib in anaplastic thyroid carcinoma.

BRCA1
Associated Cancer Type(s): Prostate Cancer, Ovarian Cancer, Pancreatic Cancer, Breast Cancer, Osteosarcoma.

Significance/Prognosis: A key gene in homologous recombination repair deficiency (HRD). Germline mutations are associated with familial cancer syndromes like Li-Fraumeni.

Detection Method(s): Genetic testing, NGS (preferred).

Therapeutic Implications: Mutations predict response to PARP inhibitors (e.g., olaparib, niraparib) in prostate, ovarian, and breast cancer.

BRCA2
Associated Cancer Type(s): Prostate Cancer, Ovarian Cancer, Pancreatic Cancer, Breast Cancer, Osteosarcoma, Uterine Sarcoma (Leiomyosarcoma - LMS).

Significance/Prognosis: A key gene in homologous recombination repair deficiency (HRD). Germline mutations have significant implications for prostate cancer progression and survival.

Detection Method(s): Genetic testing.

Therapeutic Implications: Mutations predict response to PARP inhibitors (e.g., olaparib, niraparib) in prostate, ovarian, and breast cancer.

Genetic Counseling: Recommended due to high risk of inherited cancer syndromes.

BRIP1
Associated Cancer Type(s): Prostate Cancer.

Significance/Prognosis: A homologous recombination repair (HRR) gene.

Therapeutic Implications: Mutations inform the use of PARP inhibitors (e.g., olaparib).

BTK
Associated Cancer Type(s): Brain metastases.

Significance/Prognosis: Mentioned as a potential therapeutic target.

Therapeutic Implications: Mentioned in the context of brain metastases treatment.

CALR
Associated Cancer Type(s): Myeloproliferative Neoplasms (MPN), specifically Primary Myelofibrosis (PMF), Myelodysplastic Syndromes/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T).

Significance/Prognosis: A key driver mutation in PMF. Prognostic models incorporate CALR mutation status.

Detection Method(s): NGS.

Therapeutic Implications: No therapies directly target CALR mutations, but JAK2 inhibitors (e.g., Ruxolitinib) are used for Myelofibrosis regardless of driver mutation status.

CBL
Associated Cancer Type(s): Myelodysplastic Syndromes (MDS).

Significance/Prognosis: A gene in the Molecular International Prognosis Scoring System (IPSS-M) for MDS.

CCND1 (Cyclin D1)
Associated Cancer Type(s): Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), Extranodal Marginal Zone B-Cell Lymphoma (EMZL), Splenic Marginal Zone Lymphoma (SMZL).

Significance/Prognosis: Typically positive in MCL (CD5+, CCND1+) and negative in FL. Helps in diagnosis of EMZL and SMZL.

Detection Method(s): IHC panel, FISH.

CCNB3
Associated Cancer Type(s): Pediatric undifferentiated sarcomas.

Significance/Prognosis: A genetic aberration found in pediatric undifferentiated sarcomas.

Therapeutic Implications: BCOR::CCNB3 fusion-positive tumors can be treated like Ewing sarcoma.

CD79B
Associated Cancer Type(s): Primary Cutaneous B-Cell Lymphomas (PCBCL).

Significance/Prognosis: Mutations help in distinguishing PC-DLBCL, leg type from PCFCL.

Detection Method(s): Next-Generation Sequencing (NGS).

CDK4/6
Associated Cancer Type(s): Breast Cancer, Uterine Sarcoma.

Therapeutic Implications: CDK4/6 inhibitors (e.g., abemaciclib, ribociclib) are used for HR-positive, HER2-negative breast cancer.

CDK12
Associated Cancer Type(s): Prostate Cancer.

Significance/Prognosis: A homologous recombination repair (HRR) gene.

Therapeutic Implications: Mutations inform the use of PARP inhibitors (e.g., olaparib, talazoparib).

CDKN1B (p27)
Associated Cancer Type(s): Hairy Cell Leukemia (HCL), Small Bowel Carcinoid tumors, GEP-NETs.

Significance/Prognosis: Recurrent mutations in HCL. Loss of expression is an adverse prognostic factor in GEP-NETs.

CDKN2A
Associated Cancer Type(s): Gliomas, Mesothelioma, Uterine Sarcoma (Leiomyosarcoma - LMS).

Significance/Prognosis:

Homozygous deletion is a strong adverse prognostic factor in gliomas and is common in mesothelioma.

Prognostic significance in malignant peritoneal mesothelioma.

Detection Method(s): FISH.

CDX2
Associated Cancer Type(s): Metastatic carcinoma to the lung.

Detection Method(s): IHC stain.

CEBPA
Associated Cancer Type(s): Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS).

Significance/Prognosis:

In-frame bZIP mutations are associated with favorable outcomes in AML.

Germline mutations are seen in familial AML.

A main effect gene in the IPSS-M for MDS.

Detection Method(s): Molecular and genetic testing.

CHGA (Chromogranin A)
Associated Cancer Type(s): Neuroendocrine tumors (NETs), Pancreatic Neuroendocrine Tumors, Small Cell Lung Carcinoma (SCLC).

Significance/Prognosis: A secreted protein often elevated in NETs; elevated levels have been associated with poorer prognosis.

CHIC2 deletion
Associated Cancer Type(s): Myeloid/Lymphoid Neoplasms with Eosinophilia (MLNE), specifically FIP1L1::PDGFRA rearrangement; Systemic Mastocytosis (SM).

Significance/Prognosis: A surrogate for the FIP1L1::PDGFRA fusion.

Detection Method(s): FISH, nested RT-PCR, RT-qPCR.

CHOP (fusion partner)
Associated Cancer Type(s): Myxoid liposarcoma.

Significance/Prognosis: TLS-CHOP fusion transcript structure is a prognostic factor.

CIC
Associated Cancer Type(s): Pediatric undifferentiated sarcomas.

Therapeutic Implications: CIC::DUX4 fusion-positive tumors can be treated like Ewing sarcoma.

CLDN4 (Claudin-4)
Associated Cancer Type(s): Mesothelioma.

Detection Method(s): IHC marker.

COMPLEX KARYOTYPE (CK)
Associated Cancer Type(s): Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), T-Cell Prolymphocytic Leukemia (TPLL).

Significance/Prognosis:

A poor prognostic factor in AML, often associated with TP53 mutation.

A strong predictor of inferior outcome in relapsed/refractory CLL treated with ibrutinib.

Detection Method(s): Karyotyping.

CREBBP
Associated Cancer Type(s): Follicular Lymphoma (FL).

Detection Method(s): Next-Generation Sequencing (NGS) panel.

CSF1R
Associated Cancer Type(s): Histiocytic Neoplasms (LCH, ECD, RDD).

Therapeutic Implications: Pexidartinib is a useful targeted therapy.

CTNNB1 (beta-catenin)
Associated Cancer Type(s): Sporadic desmoid tumors, Wilms Tumor, Medulloblastomas (WNT-activated).

Significance/Prognosis: Specific mutations correlate with recurrence in desmoid tumors. WNT-activated medulloblastomas have a markedly better prognosis.

CUL1
Associated Cancer Type(s): Malignant Pleural Mesothelioma.

Significance/Prognosis: Has recurrent alterations in malignant pleural mesothelioma.

CXCR4
Associated Cancer Type(s): Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL), Multiple Myeloma (MM).

Therapeutic Implications: The presence of this mutation may influence the choice or efficacy of Bruton’s tyrosine kinase (BTK) inhibitors.

DAXX
Associated Cancer Type(s): Uterine Sarcoma (Leiomyosarcoma - LMS).

Significance/Prognosis: Commonly altered in LMS. Abnormal expression by IHC may favor LMS diagnosis.

DDX41
Associated Cancer Type(s): Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML).

Significance/Prognosis: Germline mutations define a significant entity within adult MDS/AML.

Therapeutic Implications: A somatic "2nd hit" warrants timely referral for HCT evaluation.

DGCR8
Associated Cancer Type(s): Wilms tumor.

Significance/Prognosis: One of the most common somatic variants in Wilms tumor.

DIAPH1
Associated Cancer Type(s): Myeloid/Lymphoid Neoplasms with Eosinophilia (MLNE).

Significance/Prognosis: A partner gene for PDGFRB fusion.

DICER1
Associated Cancer Type(s): Uterine sarcomas.

Significance/Prognosis: Has recurrent genetic alterations in uterine sarcomas.

DNMT3A
Associated Cancer Type(s): AML, BPDCN, MDS, T-Cell Lymphomas, CML, MLNE.

Significance/Prognosis:

Has prognostic significance in AML.

One of the most frequently mutated genes in clonal hematopoiesis of indeterminate potential (CHIP).

Frequently mutated in MDS and nodal T-follicular helper (TFH) cell lymphomas.

DUX4
Associated Cancer Type(s): Pediatric undifferentiated sarcomas.

Therapeutic Implications: CIC::DUX4 fusion-positive tumors can be treated like Ewing sarcoma.

DUSP22
Associated Cancer Type(s): Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders (PCTLD), Anaplastic Large-Cell Lymphoma (ALCL), ALK negative.

Significance/Prognosis: Associated with high-risk ALK-negative ALCL.

Detection Method(s): FISH.

EBV (Epstein-Barr virus)
Associated Cancer Type(s): Richter Transformation of CLL, Post-Transplant Lymphoproliferative Disorders (PTLD), Extranodal NK/T-Cell Lymphomas, and others.

Significance/Prognosis: EBV evaluation is critical in PTLD and other lymphomas.

Detection Method(s): EBER-ISH, IHC (LMP1, EBNA2), Quantitative EBV PCR.

EGFR
Associated Cancer Type(s): Non-Small Cell Lung Cancer (NSCLC), Gliomas.

Significance/Prognosis: EGFR amplification is a high-yield alteration in gliomas. Exon 19 deletion or L858R mutations are associated with less benefit from PD-1/PD-L1 inhibitors in NSCLC.

Therapeutic Implications:

NSCLC: EGFR TKIs (e.g., osimertinib, afatinib) are used for specific mutations. EGFRex20 insertions are targeted by specific agents.

EIF1AX
Associated Cancer Type(s): Uveal Melanoma.

Significance/Prognosis: Mutations are associated with low risk for distant metastasis.

EIF6
Associated Cancer Type(s): Shwachman-Diamond Syndrome (associated with MDS/AML predisposition).

Significance/Prognosis: Somatic mutations are associated with the syndrome.

ERBB2 (HER2)
Associated Cancer Type(s): Breast Cancer, Ovarian Cancer, Gastric Cancer, NSCLC, and many others.

Significance/Prognosis: HER2 status is a critical prognostic and predictive biomarker.

Detection Method(s): IHC, ISH (FISH).

Therapeutic Implications:

Breast Cancer: Trastuzumab deruxtecan for HER2-low disease. Neratinib for HER2-mutated disease.

NSCLC: Trastuzumab deruxtecan for HER2-mutated metastatic NSCLC.

Others: HER2 positivity can predict sensitivity to targeted agents in many cancers.

ERCC6L2
Associated Cancer Type(s): Marrow failure/AML, MDS, Erythroleukemia.

Significance/Prognosis: Associated with hereditary myeloid malignancy predisposition syndromes and somatic TP53 mutations.

ESR1 (Estrogen Receptor Alpha)
Associated Cancer Type(s): Breast Cancer.

Therapeutic Implications: For ESR1-mutated tumors after progression on prior endocrine therapy, elacestrant can be considered.

ETNK1
Associated Cancer Type(s): Myelodysplastic Syndromes (MDS).

Significance/Prognosis: A main effect gene in the IPSS-M for MDS.

ETV6
Associated Cancer Type(s): AML, Hereditary Myeloid Malignancy Predisposition Syndromes, MLNE, MDS, GIST.

Significance/Prognosis:

A partner gene for PDGFRA, PDGFRB, ABL1, FLT3 fusions in MLNE.

A main effect gene in the IPSS-M for MDS.

ETV6-NTRK3 is a gene fusion involved in GIST.

Therapeutic Implications: Fusions are targetable (see entries for partner genes).

EZH2
Associated Cancer Type(s): Follicular Lymphoma (FL), AML, MDS, Myeloproliferative Neoplasms (MPN).

Significance/Prognosis:

Part of the definition for AML-myelodysplasia-related (AML-MR).

A main effect gene in the IPSS-M for MDS.

Adverse mutation in primary myelofibrosis.

Therapeutic Implications: Tazemetostat (an EZH2 inhibitor) is an option for Follicular Lymphoma.

FANCA
Associated Cancer Type(s): Prostate Cancer, Fanconi Anemia (FA).

Significance/Prognosis: FA is a familial cancer susceptibility syndrome.

Therapeutic Implications: For Prostate Cancer, mutations inform the use of PARP inhibitors (e.g., talazoparib).

FANCL
Associated Cancer Type(s): Prostate Cancer.

Significance/Prognosis: A homologous recombination repair (HRR) gene.

Therapeutic Implications: Mutations inform the use of PARP inhibitors (e.g., olaparib).

FGFR (general)
Associated Cancer Type(s): Head and Neck Cancers, NSCLC, Esophageal Cancer.

Therapeutic Implications: Erdafitinib is recommended for FGFR mutations or fusions in certain settings.

FGFR1
Associated Cancer Type(s): MLNE, CMML, "Wild-type" GIST, AML.

Significance/Prognosis: One of the TK gene fusions associated with MLNE. Associated with a high incidence of T-cell lymphoblastic lymphoma/leukemia.

Therapeutic Implications:

MLNE: Pemigatinib (preferred regimen). Other TKIs include Midostaurin or Ponatinib.

Early referral to allogeneic HCT is generally recommended as the only potentially curative option.

FGFR2
Associated Cancer Type(s): Pancreatic Adenocarcinoma, Bladder Cancer.

Therapeutic Implications: FGFR2 fusions are potentially actionable in pancreatic cancer. Erdafitinib is an option for bladder cancer.

FGFR3
Associated Cancer Type(s): Bladder Cancer.

Therapeutic Implications: Erdafitinib is an option for bladder cancer.

FH (Fumarate Hydratase)
Associated Cancer Type(s): Kidney Cancer, Neuroendocrine tumors.

Significance/Prognosis: A hereditary kidney cancer gene.

Detection Method(s): IHC for FH and 2-succinocysteine (2SC).

FLT3
Associated Cancer Type(s): Acute Myeloid Leukemia (AML), MLNE, MDS.

Significance/Prognosis:

FLT3-ITD and FLT3-TKD mutations are critical prognostic and predictive markers in AML.

A partner gene in ETV6::FLT3 fusions in MLNE.

Therapeutic Implications:

AML: Gilteritinib (category 1 recommended therapy). Other options include sorafenib, quizartinib, and midostaurin in various settings.

MLNE: Clinical trial is preferred. Gilteritinib, Midostaurin, and others can be considered.

FOXP1
Associated Cancer Type(s): Myeloid/Lymphoid Neoplasms with Eosinophilia (MLNE).

Significance/Prognosis: A partner gene for PDGFRA fusion.

GATA2
Associated Cancer Type(s): Hereditary Myeloid Malignancy Predisposition Syndromes, MDS, AML.

Significance/Prognosis: GATA2 deficiency syndrome is a highly penetrant hereditary hematologic malignancy predisposition syndrome. A main effect gene in the IPSS-M for MDS.

GATA3
Associated Cancer Type(s): Metastatic carcinoma to the lung, Mesothelioma, Pheochromocytoma/Paraganglioma.

Detection Method(s): IHC marker.

GREB1
Associated Cancer Type(s): Uterine sarcomas.

Significance/Prognosis: Has recurrent genetic alterations in uterine sarcomas.

HAVCR2
Associated Cancer Type(s): Subcutaneous Panniculitis-Like T-Cell Lymphoma (SPTCL).

Detection Method(s): Germline testing for HAVCR2 mutation is useful.

HOXB13
Associated Cancer Type(s): Prostate Cancer.

Significance/Prognosis: A prostate cancer risk gene.

Genetic Counseling: Testing may have utility for family counseling.

HRAS
Associated Cancer Type(s): Salivary gland tumors.

Detection Method(s): NGS profiling is recommended.

IDH1
Associated Cancer Type(s): AML, MDS, MPN (Myelofibrosis), MLNE, CNS Tumors (Gliomas).

Significance/Prognosis:

Has prognostic significance in AML. A main effect gene in the IPSS-M for MDS.

IDH1 mutations (R132) are high-yield mutations in gliomas and predict longer survival.

Therapeutic Implications: For AML, Ivosidenib is a recommended therapy. For gliomas, Ivosidenib is an option for IDH1 mutant grade 2 astrocytoma.

IDH2
Associated Cancer Type(s): AML, BPDCN, MDS, MPN (Myelofibrosis), T-Cell Lymphomas, MLNE, CNS Tumors (Gliomas).

Significance/Prognosis:

Has prognostic significance in AML. A main effect gene in the IPSS-M for MDS.

High incidence in nodal TFH cell lymphomas.

Therapeutic Implications:

AML: Enasidenib is recommended.

MDS: Venetoclax + HMAs shows efficacy for mIDH2.

CNS Tumors: Vorasidenib is an option.

IGHV (Immunoglobulin heavy chain variable region gene)
Associated Cancer Type(s): CLL/SLL, MCL, EMZL, SMZL, WM/LPL.

Significance/Prognosis: Mutation status is a key prognostic variable in CLL/SLL and helps differentiate other B-cell malignancies.

INO80
Associated Cancer Type(s): Hepatosplenic T-Cell Lymphoma (HSTCL).

Detection Method(s): NGS panel.

JAK2
Associated Cancer Type(s): Myeloid/Lymphoid Neoplasms with Eosinophilia (MLNE), Myeloproliferative Neoplasms (MPN) including Primary Myelofibrosis (PMF), Myelodysplastic Syndromes/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T).

Significance/Prognosis:

Fusions: One of the tyrosine kinase (TK) gene fusions associated with MLNE. Common translocations include PCM1::JAK2, ETV6::JAK2, and BCR::JAK2.

CHIP: One of the most frequently mutated genes in clonal hematopoiesis of indeterminate potential (CHIP).

V617F Mutation: A key driver mutation in PMF and other MPNs. Prognostic models incorporate JAK2 mutation status.

Detection Method(s): FISH, RT-PCR, NGS.

Therapeutic Implications:

Fusions: Ruxolitinib is a preferred regimen.

Other TKIs: Fedratinib, Momelotinib, or Pacritinib.

Myelofibrosis (MF): Combination of ruxolitinib and low-dose pegylated interferon alfa-2a has shown clinical benefit.

Curative Option: Early referral to allogeneic HCT is generally recommended.

JAZF1
Associated Cancer Type(s): Uterine sarcomas.

Significance/Prognosis: Has recurrent genetic alterations in uterine sarcomas.

KIF5B
Associated Cancer Type(s): NSCLC.

Significance/Prognosis: A fusion partner with RET in NSCLC.

KIT
Associated Cancer Type(s): AML, Systemic Mastocytosis (SM), MLNE, Gastrointestinal Stromal Tumors (GIST).

Significance/Prognosis:

KIT D816V mutation is a key diagnostic and prognostic marker in SM.

Activating mutations are found in GIST and predict response to TKIs.

Detection Method(s): High-sensitivity testing for KIT D816V is recommended (ASO-qPCR, ddPCR).

Therapeutic Implications:

SM (D816V): Avapritinib and Midostaurin are preferred regimens.

GIST: Imatinib is standard. Sunitinib, regorafenib, and ripretinib are options for imatinib-resistant disease. Avapritinib is used for PDGFRA D842V-mutated GIST.

KLF2
Associated Cancer Type(s): Splenic Marginal Zone Lymphoma (SMZL).

Significance/Prognosis: Mutation status may help differentiate SMZL from other B-cell lymphomas.

KRAS
Associated Cancer Type(s): Histiocytic Neoplasms, MDS, Small Bowel Cancer, Colon/Rectal Cancer, NSCLC, Pancreatic Cancer.

Significance/Prognosis:

A common mutation in the MAPK pathway.

A main effect gene in the IPSS-M for MDS.

Therapeutic Implications:

Small Bowel/Colon/Rectal/NSCLC (G12C): Sotorasib or adagrasib are treatment options.

LEF1
Associated Cancer Type(s): CLL/SLL, Mantle Cell Lymphoma (MCL).

Significance/Prognosis: Positive in CLL/SLL.

Detection Method(s): IHC for LEF1 may help distinguish from variant CLL.

MAX
Associated Cancer Type(s): Wild-type GIST, Neuroendocrine tumors.

Significance/Prognosis: Can be somatically lost in wild-type GIST cases.

MBD4
Associated Cancer Type(s): Myeloid Malignancies (AML predisposition), Uveal Melanoma.

Significance/Prognosis: Germline deficiency predisposes to clonal hematopoiesis and early-onset AML.

MECOM
Associated Cancer Type(s): Hereditary Hematological Malignancies.

Significance/Prognosis: Associated with a heterogeneous inherited bone marrow failure syndrome.

MEN1
Associated Cancer Type(s): Neuroendocrine tumors (Multiple Endocrine Neoplasia type 1).

Therapeutic Implications: For MEN1-related insulinomas, stabilize glucose with diet, diazoxide, and/or everolimus.

MET
Associated Cancer Type(s): NSCLC.

Significance/Prognosis: METex14 skipping mutation is a specific biomarker for first-line therapy options in advanced or metastatic NSCLC.

Therapeutic Implications: Capmatinib and tepotinib are preferred regimens. Crizotinib also has activity.

METEX14 (MET exon 14 skipping mutation)
Associated Cancer Type(s): NSCLC.

Significance/Prognosis: An actionable alteration in NSCLC.

Therapeutic Implications: See MET entry.

MGMT
Associated Cancer Type(s): CNS Tumors (Gliomas, Glioblastoma).

Significance/Prognosis: MGMT promoter methylation is a key marker of response to temozolomide.

MITF (Microphthalmia-Associated Transcription Factor)
Associated Cancer Type(s): Perivascular Epithelioid Cell Tumor (PEComa).

MLH1
Associated Cancer Type(s): Lynch Syndrome-associated cancers (Colorectal, Endometrial, Ovarian, Gastric, etc.).

Significance/Prognosis: One of the four main MMR genes. Loss of expression by IHC indicates dMMR/MSI-H.

Therapeutic Implications: dMMR/MSI-H status predicts response to immune checkpoint inhibitors (pembrolizumab, nivolumab, etc.).

MLL (KMT2A)
Associated Cancer Type(s): Acute Myeloid Leukemia (AML).

Significance/Prognosis: MLL rearrangement has prognostic significance in AML.

MLL3 (KMT2C)
Associated Cancer Type(s): Myelodysplastic Syndromes (MDS).

Significance/Prognosis: A main effect gene in the IPSS-M for MDS.

MLLT1
Associated Cancer Type(s): Wilms tumor.

Significance/Prognosis: One of the most common somatic variants in Wilms tumor.

MONOSOMAL KARYOTYPE
Associated Cancer Type(s): Acute Myeloid Leukemia (AML).

Significance/Prognosis: A poor prognostic factor, often associated with TP53 mutation.

MONOSOMY 7
Associated Cancer Type(s): AML, CML, MDS.

Significance/Prognosis: An unfavorable cytogenetic prognosticator.

MPL
Associated Cancer Type(s): Myeloproliferative Neoplasms (MPN), specifically Primary Myelofibrosis (PMF), MDS/MPN-RS-T.

Significance/Prognosis: A key driver mutation in PMF. Prognostic models incorporate MPL mutation status.

MRE11A
Associated Cancer Type(s): Prostate Cancer.

Significance/Prognosis: A homologous recombination repair (HRR) gene.

Therapeutic Implications: Mutations inform the use of PARP inhibitors (e.g., talazoparib).

MSH2
Associated Cancer Type(s): Lynch Syndrome-associated cancers.

Significance/Prognosis: One of the four main MMR genes. Loss of expression by IHC indicates dMMR/MSI-H.

Therapeutic Implications: dMMR/MSI-H status predicts response to immune checkpoint inhibitors.

MSH6
Associated Cancer Type(s): Lynch Syndrome-associated cancers.

Significance/Prognosis: One of the four main MMR genes. Loss of expression by IHC indicates dMMR/MSI-H.

Therapeutic Implications: dMMR/MSI-H status predicts response to immune checkpoint inhibitors.

MSLN (Mesothelin)
Associated Cancer Type(s): Mesothelioma, Occult Primary Cancers.

Significance/Prognosis: Soluble mesothelin-related peptide (SMRP) is a prognostic and predictive marker in mesothelioma.

MTAP
Associated Cancer Type(s): Malignant Peritoneal Mesothelioma.

Detection Method(s): IHC.

MYC
Associated Cancer Type(s): Burkitt Lymphoma (BL), DLBCL, HGBL, HIV-related B-Cell Lymphomas, and others.

Significance/Prognosis: MYC rearrangements are hallmarks of aggressive lymphomas. HGBL with MYC and BCL2 or BCL6 rearrangements ("double-hit" or "triple-hit") has a very poor prognosis.

Detection Method(s): FISH, IHC.

MYCN
Associated Cancer Type(s): Neuroblastoma, Wilms tumor.

Significance/Prognosis: MYCN amplification in neuroblastoma correlates with advanced disease and rapid progression.

MYD88
Associated Cancer Type(s): Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL), Primary Cutaneous B-Cell Lymphomas (PCBCL).

Significance/Prognosis: MYD88 L265P is a commonly recurring mutation in WM, useful for diagnosis.

Detection Method(s): Allele-specific PCR (AS-PCR) for L265P is recommended.

Therapeutic Implications: Useful for patients considered for Bruton's tyrosine kinase (BTK) inhibitors.

MYH9
Associated Cancer Type(s): Hereditary Hematological Malignancies.

Significance/Prognosis: Associated with MYH9-related disease.

NAPSA (Napsin A)
Associated Cancer Type(s): Lung Adenocarcinoma, Squamous Cell Carcinoma, SCLC.

Significance/Prognosis: A useful IHC marker for distinguishing lung adenocarcinoma.

NBN
Associated Cancer Type(s): Prostate Cancer.

Significance/Prognosis: A homologous recombination repair (HRR) gene.

Therapeutic Implications: Mutations inform the use of PARP inhibitors (e.g., talazoparib).

NCAM1 (CD56)
Associated Cancer Type(s): Small Cell Lung Cancer (SCLC).

NCOA4
Associated Cancer Type(s): NSCLC.

Significance/Prognosis: A fusion partner with RET in NSCLC.

NF1
Associated Cancer Type(s): Myelodysplastic Syndromes (MDS), GIST.

Significance/Prognosis: Germline mutations define Neurofibromatosis type 1. NF1-associated GIST should be tested for KIT/PDGFRA mutations.

Therapeutic Implications: Data for TKI use in NF1-associated GIST are limited.

Genetic Counseling: Recommended for patients with NF1-associated GIST.

NF2
Associated Cancer Type(s): Neurofibromatosis type 2 vestibular schwannomas, Malignant Mesothelioma.

Significance/Prognosis: Prognostic significance in malignant peritoneal mesothelioma.

NKX2-1 (TTF-1)
Associated Cancer Type(s): Lung Adenocarcinoma, Squamous Cell Carcinoma, Thyroid Malignancies.

Significance/Prognosis: A key IHC marker for lung and thyroid origin.

NOTCH2
Associated Cancer Type(s): Splenic Marginal Zone Lymphoma (SMZL).

Significance/Prognosis: Mutations may be helpful to differentiate SMZL from other B-cell lymphomas.

NPM1
Associated Cancer Type(s): Acute Myeloid Leukemia (AML).

Significance/Prognosis: NPM1 mutation in the absence of FLT3-ITD or with low-ratio FLT3-ITD is a favorable prognostic marker in AML.

Detection Method(s): Quantitative real-time PCR for monitoring.

NRAS
Associated Cancer Type(s): AML, BPDCN, MDS, MLNE, Lymphoid Malignancies, Colon/Rectal Cancer.

Significance/Prognosis:

A main effect gene in the IPSS-M for MDS.

Mutations in the MAPK pathway.

NRG1
Associated Cancer Type(s): NSCLC, Pancreatic Adenocarcinoma.

Significance/Prognosis: NRG1 fusions are associated with HER2-amplified pancreatic ductal adenocarcinoma.

Therapeutic Implications: NRG1 fusions are actionable targets.

NTRK (gene fusions)
Associated Cancer Type(s): Histiocytic Neoplasms, MLNE, Cervical Cancer, HCC, Occult Primary cancers, Sarcoma, Thyroid Carcinoma, NSCLC, and many others (tumor-agnostic).

Significance/Prognosis: An emerging biomarker across many cancers.

Detection Method(s): Gene fusion assay, FISH, Pan-TRK IHC, RNA sequencing (preferred).

Therapeutic Implications: NTRK gene fusions predict response to TRK inhibitors like Larotrectinib, Entrectinib, and Repotrectinib.

NUP98 rearrangement
Associated Cancer Type(s): Acute Myeloid Leukemia (AML).

Significance/Prognosis: Has prognostic significance in AML.

PALB2
Associated Cancer Type(s): Prostate Cancer, Ovarian Cancer.

Significance/Prognosis: A homologous recombination repair (HRR) gene.

Therapeutic Implications: Mutations inform the use of PARP inhibitors (e.g., olaparib, talazoparib).

PAX5
Associated Cancer Type(s): Metastatic carcinoma to the lung.

Detection Method(s): IHC stain.

PAX8
Associated Cancer Type(s): Malignant Peritoneal Mesothelioma, Metastatic Thyroid Malignancies to the lung.

Detection Method(s): IHC stain.

PDGFRA
Associated Cancer Type(s): MLNE, CEL, SM, CMML, GIST.

Significance/Prognosis:

FIP1L1::PDGFRA is the most common fusion in MLNE and CEL.

Activating mutations in GIST predict response to TKIs. PDGFRA D842V mutation confers resistance to imatinib.

Therapeutic Implications:

MLNE/CEL: Imatinib is primary treatment.

GIST (D842V): Avapritinib is recommended.

PDGFRB
Associated Cancer Type(s): MLNE, CMML.

Significance/Prognosis: ETV6::PDGFRB is the most common fusion. Responds to imatinib.

Therapeutic Implications: Imatinib is the primary treatment.

PGR (Progesterone Receptor)
Associated Cancer Type(s): Uterine Sarcomas.

Therapeutic Implications: For ER/PR-positive uterine sarcomas, aromatase inhibitors are treatment options.

PHF6
Associated Cancer Type(s): Myelodysplastic Syndromes (MDS).

Significance/Prognosis: A residual gene in the IPSS-M for MDS.

PIK3CA
Associated Cancer Type(s): Histiocytic Neoplasms, Rhabdomyosarcoma (RMS), Breast Cancer, NSCLC, Head and Neck Cancers.

Significance/Prognosis: Mutations in the PI3K-AKT-mTOR pathway are common in many cancers.

Therapeutic Implications: Alpelisib is a treatment option for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.

PIK3R1
Associated Cancer Type(s): Hepatosplenic T-Cell Lymphoma (HSTCL).

Detection Method(s): NGS panel.

POU2F3
Associated Cancer Type(s): Small Cell Lung Cancer (SCLC).

Significance/Prognosis: A key transcription factor in a subset of SCLC.

PPM1D
Associated Cancer Type(s): Myelodysplastic Syndromes (MDS).

Significance/Prognosis: A residual gene in the IPSS-M for MDS.

PRPF8
Associated Cancer Type(s): Myelodysplastic Syndromes (MDS).

Significance/Prognosis: A residual gene in the IPSS-M for MDS.

PTCH1
Associated Cancer Type(s): Medulloblastomas (SHH-activated).

Significance/Prognosis: Defines the SHH-activated subgroup of medulloblastomas.

PTEN
Associated Cancer Type(s): Breast Cancer, Prostate Cancer, Uterine Sarcoma (LMS), Small Bowel Cancer, Thyroid Cancer.

Significance/Prognosis: A key tumor suppressor gene. Loss is common in many cancers.

Syndrome Association: Germline mutations cause Cowden Syndrome (PHTS).

Therapeutic Implications: Informs use of PI3K/AKT/mTOR pathway inhibitors.

RAD51
Associated Cancer Type(s): Prostate Cancer.

Significance/Prognosis: A homologous recombination repair (HRR) gene.

Therapeutic Implications: Mutations inform the use of PARP inhibitors (e.g., olaparib, talazoparib).

RAD51C
Associated Cancer Type(s): Prostate Cancer.

Significance/Prognosis: A homologous recombination repair (HRR) gene.

Therapeutic Implications: Mutations inform the use of PARP inhibitors (e.g., olaparib).

RB1
Associated Cancer Type(s): Uterine Sarcoma (LMS), Prostate Cancer, Neuroendocrine Tumors, Neuroblastoma.

Significance/Prognosis: Commonly altered in LMS and associated with aggressive prostate cancer.

RECEPTOR TYROSINE KINASE/RAS/PIK3CA aberrations
Associated Cancer Type(s): Rhabdomyosarcoma (RMS).

Significance/Prognosis: Found in 93% of RMS cases.

RET
Associated Cancer Type(s): Histiocytic Neoplasms, MLNE, NSCLC, Pancreatic Cancer, Sarcoma, Thyroid Carcinoma (Medullary and Anaplastic).

Significance/Prognosis: Somatic RET mutations confer an adverse prognosis in sporadic medullary thyroid carcinoma.

Therapeutic Implications:

NSCLC (fusions): Selpercatinib and pralsetinib are approved.

Thyroid (mutations/fusions): Selpercatinib and pralsetinib are regimen options.

Genetic Counseling: Recommended for medullary thyroid carcinoma due to association with MEN2 syndrome.

ROS1
Associated Cancer Type(s): NSCLC, Pancreatic Cancer, Occult Primary Cancers.

Significance/Prognosis: ROS1 rearrangements are associated with less benefit from PD-1/PD-L1 inhibitors in NSCLC.

Therapeutic Implications: Entrectinib, crizotinib, and repotrectinib are treatment options for ROS1 fusion-positive NSCLC.

RUNX1
Associated Cancer Type(s): AML, MDS, MLNE, MPN, HMMPS, SM, CMML, CML.

Significance/Prognosis:

A main effect gene in the IPSS-M for MDS.

Somatic 2nd hit of RUNX1 is a high-risk finding in HMMPS.

Therapeutic Implications: No specific therapies are mentioned for RUNX1 mutations.

SAMD9
Associated Cancer Type(s): HMMPS, MDS.

Significance/Prognosis: Associated with MIRAGE syndrome and MDS with monosomy 7.

SAMD9L
Associated Cancer Type(s): HMMPS, MDS.

Significance/Prognosis: Associated with ataxia-pancytopenia syndrome and MDS with monosomy 7.

SDHA/B/C/D
Associated Cancer Type(s): GIST, Kidney Cancer, Pheochromocytoma/Paraganglioma.

Significance/Prognosis: SDH deficiency is found in GIST lacking KIT/PDGFRA mutations and may have more indolent behavior.

Genetic Counseling: Recommended due to association with hereditary cancer syndromes.

SETBP1
Associated Cancer Type(s): Myelodysplastic Syndromes (MDS).

Significance/Prognosis: A residual gene in the IPSS-M for MDS.

SETD2
Associated Cancer Type(s): Hepatosplenic T-Cell Lymphoma (HSTCL).

Detection Method(s): NGS panel.

SFPQ
Associated Cancer Type(s): Unknown Primary Cancers.

Detection Method(s): IHC marker.

SF3B1
Associated Cancer Type(s): AML, MDS, MPN (Myelofibrosis), CLL/SLL, Uveal Melanoma.

Significance/Prognosis:

A main effect gene in the IPSS-M for MDS. Most frequently mutated splice factor in MDS.

Mutations define a specific subtype of MDS with ring sideroblasts.

Therapeutic Implications: Luspatercept is a treatment option for MDS with ring sideroblasts and SF3B1 mutation.

SBDS (Shwachman-Bodian-Diamond syndrome gene)
Associated Cancer Type(s): Hereditary Myeloid Malignancy Predisposition Syndromes.

Significance/Prognosis: Associated with bone marrow failure/AML, MDS, pancreatic insufficiency.

SIX1
Associated Cancer Type(s): Wilms tumor.

Significance/Prognosis: One of the most common somatic variants in Wilms tumor.

SIX2
Associated Cancer Type(s): Wilms tumor.

Significance/Prognosis: One of the most common somatic variants in Wilms tumor.

SMARCA4
Associated Cancer Type(s): Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT).

SOX10
Associated Cancer Type(s): Melanoma, Cutaneous Melanoma.

Detection Method(s): IHC marker.

SOX11
Associated Cancer Type(s): Mantle Cell Lymphoma (MCL).

Significance/Prognosis: Expression helps identify cyclin D1-negative MCL.

SRP72
Associated Cancer Type(s): Hereditary Myeloid Malignancy Predisposition Syndromes.

Significance/Prognosis: Associated with familial aplasia and myelodysplasia.

SRSF2
Associated Cancer Type(s): AML, BPDCN, CML, CMML, MDS, MPN (Myelofibrosis).

Significance/Prognosis:

A main effect gene in the IPSS-M for MDS.

Adverse mutation in primary myelofibrosis.

STAG2
Associated Cancer Type(s): Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS).

Significance/Prognosis: A main effect gene in the IPSS-M for MDS.

STAT3
Associated Cancer Type(s): T-LGLL, ANKL, MDS, HSTCL, ATLL.

Significance/Prognosis: Mutations are commonly found in T-cell LGL disease.

STAT5B
Associated Cancer Type(s): T-LGLL, ANKL, HSTCL.

Significance/Prognosis: Mutational analysis is useful for T-LGLL.

STAT6
Associated Cancer Type(s): Follicular Lymphoma (FL).

Detection Method(s): NGS panel.

SYT (fusion partner)
Associated Cancer Type(s): Synovial sarcoma.

Significance/Prognosis: SYT-SSX fusion is a hallmark of synovial sarcoma.

TCR (T-cell receptor gene rearrangement)
Associated Cancer Type(s): T-Cell Lymphomas (various subtypes).

Significance/Prognosis: Detection of clonal TCR gene rearrangements is a key diagnostic tool for T-cell malignancies.

TCL1
Associated Cancer Type(s): T-Cell Prolymphocytic Leukemia (TPLL).

Significance/Prognosis: Overexpression is a major criterion for TPLL diagnosis.

TERT promoter
Associated Cancer Type(s): CNS Tumors (Gliomas, Glioblastomas).

Significance/Prognosis: TERT promoter mutations are associated with poor prognosis in gliomas.

TFE3
Associated Cancer Type(s): Perivascular Epithelioid Cell Tumor (PEComa).

Significance/Prognosis: TFE3 gene fusions define a subset of PEComas.

TET2
Associated Cancer Type(s): AML, BPDCN, MDS, MLNE, MPN, T-Cell Lymphomas.

Significance/Prognosis:

One of the most frequently mutated genes in clonal hematopoiesis of indeterminate potential (CHIP).

Frequently mutated in MDS and nodal TFH cell lymphomas.

Therapeutic Implications: Patients with mutated TET2 in MDS had a higher response rate to Azacitidine.

TET3
Associated Cancer Type(s): Hepatosplenic T-Cell Lymphoma (HSTCL).

Detection Method(s): NGS panel.

TLS (fusion partner)
Associated Cancer Type(s): Myxoid liposarcoma.

Significance/Prognosis: TLS-CHOP fusion transcript structure is a prognostic factor.

TNFRSF14
Associated Cancer Type(s): Follicular Lymphoma (FL).

Detection Method(s): NGS panel.

TP53
Associated Cancer Type(s): AML, MCL, CLL/SLL, MDS, MPN, Sarcoma, and many others.

Significance/Prognosis:

TP53 mutations are one of the most common and prognostically significant alterations in cancer.

Associated with poor prognosis in AML, MDS, and CLL.

Germline mutations cause Li-Fraumeni syndrome.

Therapeutic Implications:

Richter Transformation (del(17p)/TP53 mut): Clinical trial, CAR T-cell therapy.

MCL (TP53 mut): Zanubrutinib, obinutuzumab, and venetoclax.

TP63 (p63/p40)
Associated Cancer Type(s): Anaplastic Large-Cell Lymphoma (ALCL), Lung Adenocarcinoma, Squamous Cell Carcinoma.

Detection Method(s): IHC.

TPSAB1
Associated Cancer Type(s): Hereditary Alpha-Tryptasemia (HαT), Systemic Mastocytosis (SM).

Significance/Prognosis: HαT is characterized by duplications/triplications in TPSAB1. Associated with elevated tryptase and increased risk of severe anaphylaxis.

TRBC1
Associated Cancer Type(s): Mycosis Fungoides/Sézary Syndrome (MF/SS), HSTCL, ATLL.

Significance/Prognosis: Can contribute to detecting T-cell clonality.

TRIM37
Associated Cancer Type(s): Wilms tumor.

Significance/Prognosis: One of the most common somatic variants.

TRISOMY 8 / +12
Associated Cancer Type(s): Desmoid Fibromatosis (+8), MDS (+8), CLL (+12), TPLL (+8), HSTCL (+8).

Significance/Prognosis: A common cytogenetic abnormality with varying prognostic impact depending on the disease.

TSC1
Associated Cancer Type(s): Perivascular Epithelioid Cell Tumor (PEComa), CNS Tumors (SEGA), Kidney Cancer, Pancreatic Neuroendocrine Tumors.

Syndrome Association: Tuberous sclerosis complex.

Therapeutic Implications: Sirolimus or everolimus for PEComa. Everolimus for SEGA.

TSC2
Associated Cancer Type(s): PEComa, CNS Tumors (SEGA), Kidney Cancer, Uterine Sarcomas.

Syndrome Association: Tuberous sclerosis complex.

Therapeutic Implications: Sirolimus or everolimus for PEComa. Everolimus for SEGA.

TTF-1 (NKX2-1)
Associated Cancer Type(s): Lung Adenocarcinoma, Squamous Cell Carcinoma, Thyroid Malignancies.

Significance/Prognosis: A key IHC marker for lung and thyroid origin.

U2AF1
Associated Cancer Type(s): AML, BPDCN, MDS, MPN (Myelofibrosis).

Significance/Prognosis:

A main effect gene in the IPSS-M for MDS.

Adverse mutation in primary myelofibrosis.

UBR5
Associated Cancer Type(s): Mantle Cell Lymphoma (MCL).

Significance/Prognosis: Mutations support the diagnosis of MCL.

VHL
Associated Cancer Type(s): CNS Hemangioblastomas, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors.

Syndrome Association: von Hippel-Lindau disease.

Therapeutic Implications: Belzutifan is a useful therapy for VHL-associated tumors (CNS Hemangioblastomas, RCC, Neuroendocrine Tumors).

WT1
Associated Cancer Type(s): MDS, Wilms tumor, Unknown Primary Cancers, Mesothelioma.

Significance/Prognosis: A residual gene in the IPSS-M for MDS. A key tumor suppressor gene in Wilms tumor.

WTX (AMER-1)
Associated Cancer Type(s): Wilms tumor.

Significance/Prognosis: One of the most common somatic variants in Wilms tumor.

ZRSR2
Associated Cancer Type(s): Acute Myeloid Leukemia (AML), BPDCN, MDS, MLNE.

Significance/Prognosis: A main effect gene in the IPSS-M for MDS. Frequently mutated in MDS.

Detection Method(s): Next-Generation Sequencing (NGS).